

CANCER CARE DELIVERY (CCD) COMMITTEE

Co-Chairs: Dawn L. Hershman, M.D., M.S.
Scott D. Ramsey, M.D., Ph.D.
Veena Shankaran, M.D.

Agenda

Up-and-Coming Studies

S1912CD, “Randomized Trial of a Proactive Financial Navigation Intervention for Cancer Patients and Caregivers,” Veena Shankaran, M.D., University of Washington

SXXXXCD, **Feasibility and Efficacy Study of the Implementation of an Educationally Enhanced Genomic Tumor Board (GTB) at NCORP Sites to Improve Understanding and Application of Genomic Tumor Testing (GTT)**, Jens Rueter, MD, Maine Cancer Genomics Initiative

S1904, “Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ,” Katherine Crew, MD, MS and Rita Kukafka, DrPH, MA, Columbia University Irving Medical Center

Active Studies

S1703, “Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer,” Dr. M. Accordino. Activated 7/16/18.

S1916, “Feasibility of a Digital Health Offering in Optimizing Opioid Pain Control in Cancer Patients,” Dawn Hershman, M.D., Sherry Shen, M.D. Columbia University Irving Medical Center. (Pilot study sponsored by Proteus).

S1415CD, “A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER).” Drs. S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16.

New Study Ideas

S2010, **Active Symptom Monitoring in Young Women with Breast Cancer**, Lynn Henry, MD, PhD, University of Michigan

Examining Clinical Work Intensity Among Medical Oncologists: Follow Up, Matt Hudson, PhD, MPH, Prisma Health

Closed Studies

S1204, “A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV) and Hepatitis C (HCV) Among Newly Diagnosed Cancer Patients.” Drs. S. Ramsey, R. Loomba, R. Chugh, et al. Activated: 8/29/13. Closed: 2/15/17.

S1400 (Genomics), “Ancillary Study to Evaluate Patient & Physician Knowledge, Attitudes, and Preferences Related to Return of Genomic Results in SWOG 1400 (Lung-MAP).” Dr. J. Roth. Activated: 2/5/18. Closed: 6/30/19.

S1417CD, “Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer.” Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.

S1105, “Text Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women with Early Stage Breast Cancer,” Dr. A. Neugut. Activated: 3/27/12. Closed: 9/15/13. (Results to be presented at ASCO).

Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

S1007, Update on Quality of Life and Economic Analysis Sub-study of Breast protocol S1007. Bill Barlow, Ph.D.

S1207, Cost Effectiveness Analysis of “Phase III Randomized, Placebo-controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-risk, Hormone Receptor-positive and HER2 Negative Breast Cancer.” Dr. Chavez-MacGregor

S1806, Healthcare Cost Comparison of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle-invasive Bladder Cancer, Dr. R. Vaidya, Dr. J. Unger

S1826, Health Economic Substudy of “Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma”. Drs. A. Prica, M. Cheung, S. Parsons, R. Vaidya.

Database/Grant Funded Projects

Published

Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. Mariana Chavez-MacGregor, M.D. Published in *Cancer*, April 2018.

Osteoporosis in Patients with Colorectal Cancer Enrolled on SWOG Trials. Afsaneh Barzi, M.D. Published in *Arch Osteoporos*, July 2019

Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. Joseph Unger, Ph.D. Published in *JAMA Network Open*, August 2018.

Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. Joseph Unger, Ph.D. Published in *JNCI*, August 2016.

Association between Body Mass Index and Response to Duloxetine for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in SWOG S1202. Lynn Henry, M.D. Published in *Cancer*, June 2019.

Ongoing

Sex Differences in Adverse Event Reporting in SWOG Chemotherapy, Biologic/Immunotherapy and Targeted Agent Cancer Clinical Trials. Joseph Unger, Ph.D.

Analysis of Accrual Patterns of Adolescent & Young Adult (AYA) Patients to A National Cooperative Research Group Over 25 years: The SWOG Experience. Mark Lewis, M.D.

Positive Clinical Trial Treatment Effects within Demographic and Insurance Status Subsets. Joseph Unger, Ph.D.

Association of BMI categories and healthcare utilization and costs among patients with the four most common cancers. Mariana Chavez-MacGregor, M.D.

Long-term Complications of Treatment for Prostate Cancer. Joseph Unger, Ph.D.

The Association of Baseline Cardiovascular Risk Factors and Healthcare Utilization and Costs in Elderly Breast Cancer Patients Enrolled in SWOG Clinical Trials. Dawn Hershman, M.D.